News | Stethoscopes | December 30, 2019

Eko Announces Redesigned CORE Product Line

The redesigned Eko CORE offers active noise cancellation, sleeker design and powerful software to allow medical professionals to more effectively screen for heart disease

eko chest shot

December 30, 2019 — Eko, a digital health company with an AI-powered cardiac screening platform, announced the second generation of its CORE product line. An evolution from Eko's first-generation CORE, the new CORE features powerful amplification and active noise cancellation that enables doctors and nurses to hear heart and lung sounds with greater clarity and screen patients for heart disease, the number one cause of death in the U.S., more effectively.

“When heart and lung sounds are amplified in the screening of heart valve and pulmonary diseases, everything changes,” said Connor Landgraf, co-founder and CEO of Eko. “Our mission at Eko continues to be to enable all healthcare professionals to provide the highest level of cardiac care through non-invasive, reliable products. The redesigned CORE puts the ears of a trained cardiologist in the hands of any doctor or nurse.”

Two hundred years after its invention, the stethoscope is still the most heavily relied upon cardiac and pulmonary screening tool. With a sleeker design, unprecedented active noise cancellation, and forthcoming decision support algorithms, the second-generation CORE will elevate what clinicians already use in every physical exam and close gaps in care created in part by analog stethoscopes.

“The better we can hear and the better we can screen, the better we can care for our patients,” said Dr. Steve Pham, VP of clinical research at Eko and an emergency medicine physician. “The CORE, coupled with Eko’s software, helps convert the device already worn around the neck of 30 million clinicians around the world into a powerful cardiopulmonary screening tool.” 

Since releasing its first-generation CORE in 2015, clinicians at over 4,000 hospitals have used the device to enhance their practice.

The second-generation CORE will be available on Eko’s website to healthcare providers as an attachment to their existing stethoscope (sold as the CORE Digital Attachment) or as a fully assembled digital stethoscope (sold as the CORE Digital Stethoscope) for $199 and $249, respectively.

CORE Digital Attachment and CORE Digital Stethoscope features include: 

  • Active noise-cancellation, perfect for honing in on heart and lung sounds in loud settings 
  • 40x sound amplification with seven volume settings, for enhanced clarity of critical sounds 
  • Easy toggling between acoustic and digital modes 
  • Lithium-ion battery with 10-hour life and micro-USB charging
  • Wireless Bluetooth connection to Eko’s software
  • Save 15, 30, 60 or 120-second recordings with “one click” recording button 

Eko’s software allows users to capture, analyze and share sound data:

  • View sound waveforms and phonocardiograms
  • Eko’s screening algorithms, currently FDA-pending, will assist clinicians in analyzing heart sounds for pathologic murmurs and valvular heart diseases
  • Share recordings with colleagues for a second opinion or live stream cardiology-grade sounds with an Eko Enterprise plan, which powers reliable real-time connections between clinicians and patients, or between clinicians for second opinions 

Eko’s screening algorithms are in development and have not been cleared by the FDA.

For more information: www.ekohealth.com


Related Content

News | Cardiac Diagnostics

September 15, 2022 - Happitech has announced the launch of its FastStart Research app. The Amsterdam-based digital ...

Home September 15, 2022
Home
Feature | Cardiac Diagnostics | by Kelly Patrick

Like most healthcare markets, the diagnostic cardiology market has had a bumpy ride in recent years. The COVID-19 ...

Home August 23, 2022
Home
Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

Home October 29, 2021
Home
News | Cardiac Diagnostics

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

Home October 04, 2021
Home
News | Cardiac Diagnostics

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

Home September 28, 2021
Home
News | Cardiac Diagnostics

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation ...

Home July 29, 2021
Home
News | Cardiac Diagnostics

July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation ...

Home July 01, 2021
Home
Subscribe Now